Robust automated cell counter and viability measurement for engineered T cell product release von Ohayon, Y, Corl, C.M, Leskowitz, R.M, Malykhin, A, Arostegui, S.M, Hennesy, N.A, Ngo, S, Levine, B.L, Siegel, D, Fesnak, A, Davis, M.M

Volltext

Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells von Gohil, M, Dai, A, Mackey, S, Negorev, D, Hennesy, N.A, O'Rourke, M, Lamontagne, A, Holland, D, Leskowitz, R.M, Xu, J, Ozerova, M, McKee, J.S, Pequignot, E, Siegel, D, Schuster, S, Svoboda, J, Garfall, A, Cohen, A, Stadtmauer, E, Gladney, W, Levine, B.L, Fraietta, J.A, Davis, M.M

Volltext

Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) von Davis, M.M, Fesnak, A, Leskowitz, R.M, McKee, J.S, Ohayon, Y, Corl, C.M, Malykhin, A, Fraietta, J.A, Joseph Melenhorst, J, June, C, Schuster, S, Levine, B.L

Volltext

14 - Regulatory Affairs, Quality Systems, Policy, and Ethics: FDA CYTOTOXICITY AND POTENCY REVIEW: OPPORTUNITIES FOR ASSAY CLARITY von Barber-Rotenberg, J.S., Leskowitz, R.M., Jadlowsky, J., Hexner, E., Binder, Z.A., Bhoj, V.G., Siegel, D., Fraietta, J.A., O’Rourke, D., Levine, B.L., Chew, A., June, C.

Volltext

Regulatory Affairs, Quality Systems, Policy, and Ethics: FDA CYTOTOXICITY AND POTENCY REVIEW: OPPORTUNITIES FOR ASSAY CLARITY von Barber-Rotenberg, J.S., Leskowitz, R.M., Jadlowsky, J., Hexner, E., Binder, Z.A., Bhoj, V.G., Siegel, D., Fraietta, J.A., O’Rourke, D., Levine, B.L., Chew, A., June, C.

Volltext

Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products von Gladney, W., Hexner, E., Salas-McKee, J., Fesnak, A., Jadlowsky, J., Plesa, G., Leskowitz, R.M., Chew, A., Dai, A., Gohil, M., Xu, J., Siegel, D., Lacey, S., Davis, M.M., June, C.

Volltext

Large-scale manufacture of car T cells engineered with augmented proliferative capacity and function via a 3-day process von Gohil, M., Xu, J., McKee, J.S., Rojas Levine, J., Hasenmayer, D., Eby, P., Dai, A., Mackey, S., Jain, A., Haines, K.M., Koterba, N., Kulikovskaya, I., Gupta, M., Chen, F., Gonzalez, V.E., Gabunia, K., Scholler, J., Young, R., Siegel, D., Levine, B.L., Chew, A., June, C., Leskowitz, R.M., Lacey, S., Plesa, G., Davis, M.M.

Volltext

195 - Robust automated cell counter and viability measurement for engineered T cell product release von Ohayon, Y., Corl, C.M., Leskowitz, R.M., Malykhin, A., Arostegui, S.M., Hennesy, N.A., Ngo, S., Levine, B.L., Siegel, D., Fesnak, A., Davis, M.M.

Volltext

180 - Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) von Davis, M.M., Fesnak, A., Leskowitz, R.M., McKee, J.S., Ohayon, Y., Corl, C.M., Malykhin, A., Fraietta, J.A., Joseph Melenhorst, J., June, C., Schuster, S., Levine, B.L.

Volltext